Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα)

Journal of Biological Chemistry

Volumn 289, Issue 36, 2014, Pages 25227-25240

  Dan, Han C ^a,d   Ebbs, Aaron ^a   Pasparakis, Manolis ^b   Van Dyke, Terry ^c   Basseres, Daniela S ^a   Baldwin, Albert S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; CHEMICAL ACTIVATION; ENZYMES; MAMMALS; PHOSPHORYLATION;

CANCER CELL LINES; CELL SURVIVAL; KINASE COMPLEX; MAMMALIAN TARGET; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); NEGATIVE REGULATORS; PROTEIN KINASE; TUBEROUS SCLEROSIS;

ANTIBIOTICS;

I KAPPA B KINASE ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; SERINE; I KAPPA B KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN BINDING; RPTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RAT; REGULATORY MECHANISM; ANIMAL; CELL CULTURE; CELL PROLIFERATION; FEMALE; GENETICS; HEK293 CELL LINE; HELA CELL LINE; IMMUNOBLOTTING; KNOCKOUT MOUSE; METABOLISM; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; ENZYME ACTIVATION; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; I-KAPPA B KINASE; IMMUNOBLOTTING; MALE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SERINE; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84906971768     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.554881     Document Type: Article

References (58)

1. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011) mTOR: from growth signal integration to cancer, diabetes, and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35
2. Howell, J. J., and Manning, B. D. (2011) mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metab. 22, 94-102
3. Inoki, K., Kim, J., and Guan, K.-L. (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 52, 381-400
4. Jewell, J. L., Guan, K. L. (2013) Nutrient signaling to mTOR and cell growth. Trends Biochem. Sci. 38, 233-242
5. Ma, X. M., and Blenis, J. (2009) Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318
6. Dai, N., Rapley, J., Angel, M., Yanik, M. F., Blower, M. D., and Avruch, J. (2011) mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev. 25, 1159-1172
7. Kim, J., Kundu, M., Viollet, B., and Guan, K. L. (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132-141
8. Cybulski N, Hall M. N. (2009) TOR complex 2: a signaling pathway of its own. Trends Biochem. Sci. 34, 620-627
9. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
10. García-Martínez, J. M., and Alessi, D. R. (2008) mTORC2 controls hydrophobic motif phosphorylation and activation of SGK1. Biochem. J. 416, 375-385
11. Yan, L., Mieulet, V., and Lamb, R. (2008) mTORC2 is the hydrophobic motif kinase for SGK1. Biochem. J. 416, e19-e21
12. Alessi, D. R., Pearce, L. R., García-Martínez, J. M. (2009) New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal. 2, pe27
13. Shaw, R. J., and Cantley, L. C. (2006) Ras, PI3K, and mTOR signaling controls tumor growth. Nature 441, 424-430
14. Rosen, N., and She, Q. B. (2006) Akt and cancer: is it all mTOR? Cancer Cell 10, 254-256
15. Manning, B. D., and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274
16. Bhaskar, P. T., and Hay, N. (2007) The two TORCs and Akt. Dev. Cell 12, 487-502
17. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., and Cantley, L. C. (2002) Identification of the TSC2 tumor suppressor gene product tuberin as a target of the PI3K/Akt pathway. Mol. Cell 10, 151-162
18. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.-L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol. 4, 648-657
19. Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., and Pan, D. (2003) Rheb is a direct target of the tuberous sclerosis tumor suppressor proteins. Nat. Cell Biol. 5, 578-581
20. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., and Avruch, J. (2005) Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702-713
21. Avruch, J., Long, X., Lin, Y., Ortiz-Vega, S., Rapley, J., Papageorgiou, A., Oshiro, N., and Kikkawa, U. (2009) Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to Raptor. Biochem. Soc. Trans. 37, 223-226
22. Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., and Sabatini, D. M. (2007) PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915
23. Vander Haar, E., Lee, S. I., Bandhakavi, S., Griffin, T. J., and Kim, D.-H. (2007) Insulin signaling to mTOR mediated by Akt/PKB substrate PRAS40. Nat. Cell Biol. 9, 316-323
24. Wang, L., Harris, T. E., Roth, R. A., and Lawrence, J. C. (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a director inhibitor of substrate binding. J. Biol. Chem. 282, 20036-20044
25. Karin, M. (2006) Nuclear factor-κB in cancer development and progression. Nature 441, 431-436
26. Staudt, L. M. (2010) Oncogenic activation of NF-κB. Cold Spring Harb. Perspect. Biol. 2, a000109
27. Ben-Neriah, Y., and Karin, M. (2011) Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 12, 715-723
28. Hayden, M. S., and Ghosh, S. (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26, 203-234
29. Perkins, N. D. (2012) The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer. 12, 121-132
30. Baldwin, A. S. (2012) Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol. Rev. 246, 327-345
31. Lee, D. F., Kuo, H. P., Chen, C. T., Hsu, J. M., Chou, C. K., Wei, Y., Sun, H. L., Li, L. Y., Ping, B., Huang, W. C., He, X., Hung, J. Y., Lai, C. C., Ding, Q., Su, J. L., Yang, J. Y., Sahin, A. A., Hortobagyi, G. N., Tsai, F. J., Tsai, C. H., Hung, M. C. (2007) IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455
32. Huang, W. C., Ju, T. K., Hung, M. C., and Chen, C. C. (2007) Phosphorylation of CBP by IKKα promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol. Cell 26, 75-87
33. Hutti, J. E., Turk, B. E., Asara, J. M., Ma, A., Cantley, L. C., and Abbott, D. W. (2007) IκB kinase β phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-κB pathway. Mol. Cell. Biol. 27, 7451-7461
34. Comb, W. C., Hutti, J. E., Cogswell, P., Cantley, L. C., and Baldwin, A. S. (2012) p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol. Cell 45, 719-730
35. Marinis, J. M., Hutti, J. E., Homer, C. R., Cobb, B. A., Cantley, L. C., Mc- Donald, C., and Abbott, D. W. (2012) IκB kinase α phosphorylation of TRAF4 down-regulates innate immune signaling. Mol. Cell. Biol. 32, 2479-2489
36. Liu, M., Lee, D.-F., Chen, C.-T., Yen, C.-J., Li, L.-Y., Lee, H.-J., Chang, C.-J., Chang, W.-C., Hsu, J.-M., Kuo, H.-P., Xia, W., Wei, Y., Chiu, P. C., Chou, C. K., Du, Y., Dhar, D., Karin, M., Chen, C. H., and Hung, M. C. (2012) IKKα activation of Notch links tumorigenesis via FoxA2 suppression. Mol. Cell 45, 171-184
37. Dan, H. C., Adli, M., and Baldwin, A. S. (2007) Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by IKKα. Cancer Res. 67, 6263-6269
38. Dan, H. C., Cooper, M. J., Cogswell, P. C., Duncan, J. A., Ting, J. P., and Baldwin, A. S. (2008) Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 22, 1490-1500
39. Dan, H. C., and Baldwin, A. S. (2008) Differential involvement of IKKα and -β in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J. Immunol. 180, 7582-7589
40. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175
41. Ekim, B., Magnuson, B., Acosta-Jaquez, H. A., Keller, J. A., Feener, E. P., and Fingar, D. C. (2011) mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol. Cell. Biol. 31, 2787-2801
42. Gareus, R., Huth, M., Breiden, B., Nenci, A., Rösch, N., Haase, I., Bloch, W., Sandhoff, K., and Pasparakis, M. (2007) Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. Nat. Cell Biol. 9, 461-469
43. Hu, M. C., Lee, D. F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J. Y., Zou, Y., Bao, S., Hanada, N., Saso, H., Kobayashi, R., and Hung, M. C. (2004) IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237
44. Madrid, L. V., Wang, C. Y., Guttridge, D. C., Schottelius, A. J., Baldwin, A. S., Jr., and Mayo, M. W. (2000) Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol. Cell. Biol. 20, 1626-1638
45. Gustin, J. A., Korgaonkar, C. K., Pincheira, R., Li, Q., and Donner, D. B. (2006) Akt regulates basal and induced processing of NF-κB2 (p100) to p52. J. Biol. Chem. 281, 16473-16481
46. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., Donner, D. B. (1999) NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82-85
47. Criollo, A., Senovilla, L., Authier, H., Maiuri, M. C., Morselli, E., Vitale, I., Kepp, O., Tasdemir, E., Galluzzi, L., Shen, S., Tailler, M., Delahaye, N., Tesniere, A., De Stefano, D., Younes, A. B., Harper, F., Pierron, G., Lavandero, S., Zitvogel, L., Israel, A., Baud, V., and Kroemer, G. (2010) The IKK complex contributes to the induction of autophagy. EMBO J. 29, 619-631
48. Comb, W. C., Cogswell, P., Sitcheran, R., and Baldwin A. S. (2011) IKK-dependent, NF-κB-independent control of autophagic gene expression. Oncogene 30, 1727-1732
49. Vivanco I., and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501
50. Hay, N. (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8, 179-183
51. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., Loda, M., Lane, H. A., and Sellers, W. R. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601
52. Plas, D. R., and Thompson, C. B. (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435-7442
53. Skeen, J. E., Bhaskar, P. T., Chen, C.-C., Chen, W. S., Peng, X.-D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H., and Hay, N. (2006) Akt defiency impairs normal cell proliferation and suppressesoncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10, 269-280
54. Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J. H., Mullholland, D. J., Magnuson, M. A., Wu, H., and Sabatini, D. M. (2009) (mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-159
55. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi PP. (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27, 222-224
56. You, M. J., Castrillon, D. H., Bastian, B. C., O'Hagan, R. C., Bosenberg, M. W., Parsons, R., Chin, L., and DePinho, R. A. (2002) Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 99, 1455-1460
57. Ma, L., Teruya-Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon-Cardo, C., and Pandolfi, P. P. (2005) Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19, 1779-1786
58. Nardella, C., Chen, Z., Salmena, L., Carracedo, A., Alimonti, A., Egia, A., Carver, B., Gerald, W., Cordon-Cardo, C., and Pandolfi, P. P. (2008) Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22, 2172-2177